Refractory Anemia With Excess Blasts: Clinical Trials

2 trials for Refractory Anemia With Excess Blasts, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2

Follow Refractory Anemia With Excess Blasts: new trials by email Literature Review of Refractory Anemia With Excess Blasts trials Research Report on Refractory Anemia With Excess Blasts

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
rigosertib sodium - Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts
Phase 3CompletedTraws Pharma, Inc.672013-08-012020-06-30
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
asparaginase, daunorubicin hydrochloride, fludarabine phosphate - Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
Phase 3CompletedNational Cancer Institute (NCI)8801996-08-012013-01-16

Narrower conditions

Anemia, Refractory, with Excess of Blasts (2)  ·  Leukemia, Myelomonocytic, Chronic (2)  ·  Anemia, Refractory (1)  ·  Cytopenia (1)  ·  Myelodysplastic Syndromes (1)

Broader conditions

Anemia (2)  ·  Bone Marrow Diseases (2)  ·  Chronic Disease (2)  ·  Disease Attributes (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Leukemia (2)  ·  Leukemia, Myeloid (2)  ·  Myelodysplastic-Myeloproliferative Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Anemia, Refractory (1)  ·  Myelodysplastic Syndromes (1)

Interventions

Asparaginase (1)  ·  Busulfan (1)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Cytarabine (1)  ·  Daunorubicin (1)  ·  Dexamethasone (1)  ·  Etoposide (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Hydrocortisone (1)  ·  Idarubicin (1)  ·  Interleukin-2 (1)  ·  Methotrexate (1)  ·  ON 01910 (1)

Sponsors

National Cancer Institute (NCI) (1)  ·  Traws Pharma, Inc. (1)

Countries

United States (2)  ·  Australia (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Beverly Lange (1)  ·  Steven M. Fruchtman, MD (1)

Results publications

PMID 19304957, PMID 20056794, PMID 20413658, PMID 36815378, PMID 38295280, PMID 42085603

NIH funding

U10CA098543 (1)